Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

The first curative interstitial photodynamic therapy for patients with localised recurrent prostate cancer

Reference number
Coordinator SPECTRACURE AB (PUBL) - SpectraCure AB
Funding from Vinnova SEK 500 000
Project duration July 2017 - November 2017
Status Completed

Purpose and goal

The project´s goal was to develop a business plan for validation and commercialisation of SpectraCure´s method of treating patients with relapsed prostate cancer after radiotherapy. In addition, the business plan has been expanded to include primary treatment of prostate cancer patients. The latter patient group is a much larger market, but with a number of established treatment methods. The positive preliminary results from ongoing clinical study mean that we believe that our method should have a very good opportunity to establish itself as a standard treatment.

Expected results and effects

We have now updated the company´s business plan according to the Horizon 2020 phase 1 application. The following changes mean that we are now better equipped to meet the needs of the market and our patients: 1. Position our method as a primary treatment modality 2. Enable local / focal treatment of prostate cancer Overall, this will increase our potential market and offer our patients an flexible, and hopefully, more sophisticated method than the existing standard of care. This has been achieved through technical, clinical and economic development work.

Planned approach and implementation

A market analysis was commissioned by the NC Biotechnology Center, which indicates that the overall market for prostate cancer will increase 50-100% over a ten-year period. In discussions with our clinical partners, we have decided to target primary tumor treatment to meet the increasing patient need. In connection to this we can now offer focal treatment of prostate cancer. This reduces the risk of side effects in patients. Overall, it gives us a excellent opportunity to establish our treatment method in a very large market segment.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 14 June 2019

Reference number 2017-03361

Page statistics